New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 11, 2013
06:11 EDTPRGOPerrigo downgraded to Sell from Neutral at Goldman
Goldman downgraded Perrigoo due to valuation and expectations for slowing growth given the delayed Mucinex launch and new baby store brand formula packaging. Price target is $110.
News For PRGO From The Last 14 Days
Check below for free stories on PRGO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
12:56 EDTPRGOPerrigo confirms AB therapeutic equivalent rating for testosterone gel 1.0%
Subscribe for More Information
July 23, 2014
10:02 EDTPRGOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTPRGODeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTPRGOPerrigo initiated with a Buy at Deutsche Bank
Target $189.
July 18, 2014
09:35 EDTPRGOPerrigo would rather make acquisitions than be sold, dealReporter says
Subscribe for More Information
July 16, 2014
11:34 EDTPRGOPerrigo management to meet with Needham
Subscribe for More Information
07:59 EDTPRGOTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
July 15, 2014
11:13 EDTPRGOPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
07:48 EDTPRGOPerrigo could be acquired, says RBC Capital
After Globes suggested that Perrigo has hired an investment bank to sell the company. RBC Capital thinks the company has several attributes that could appeal to potential acquirers, including its ability to serve as an inversion vehicle. However, the firm believes that Perrigo could also acquire another company instead. RBC Capital keeps a $160 price target and Outperform rating on the shares.
07:35 EDTPRGOPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use